
Prostate Cancer
Latest News
Latest Videos

CME Content
More News

Results from the phase III SPARTAN trial showed that apalutamide plus androgen deprivation therapy significantly improved overall survival when compared with ADT plus placebo in patients with nonmetastatic castration-resistant prostate cancer.

Imaging with 18F-DCFPyL-PET/CT outperformed that of standard imaging modalities—such as bone scan, CT, MRI, and FDG PET—in patients with biochemically relapsed prostate cancer.

Relugolix (Relumina) demonstrated superiority over leuprolide (Lupron) in sustained testosterone (T)-suppression through 48 weeks in patients with advanced prostate cancer.

Results from the TheraP trial found that in men with metastatic castration resistant prostate cancer who progressed after treatment with docetaxel, 177Lu-PSMA-617 was more active than cabazitaxel.

The National Comprehensive Cancer Network has updated its Prostate Cancer guidelines to include the PARP inhibitor rucaparib.

Decreases in local-stage and increases in distant- and regional-stage prostate cancer incidence may be the result of a recommendation by the US Preventive Services Task Force against PSA–based screenings.

Alan H. Bryce, MD, discusses the recent regulatory approval of rucaparib in metastatic castration-resistant prostate cancer and explains how the approval has underscored the importance of genetic testing in the field.

External beam radiotherapy plus androgen deprivation therapy showed superior overall survival compared with EBRT plus a brachytherapy boost in men with intermediate- and high-risk prostate cancer.

Eric A. Klein, MD, discusses the utility of Oncotype DX Genomic Prostate Score in predicting outcomes in African American men with prostate cancer.

The FDA has approved the FoundationOneCDx and BRACAnalysis CDx tests as companion diagnostics to identify patients with metastatic castration-resistant prostate cancer with homologous recombination repair mutations, making them eligible for treatment with the PARP inhibitor olaparib.

Eric A. Klein, MD, discusses the utility of Oncotype DX Genomic Prostate Score in predicting outcomes in African American men with prostate cancer.

Neeraj Agarwal, MD, provides insight into olaparib, further discusses the data that led to the regulatory approval, and shares the implications of this approval in metastatic castration-resistant prostate cancer.

Neeraj Agarwal, MD, provides insight into olaparib, further discussed the data that led to the regulatory approval, and shared the implications of this approval in metastatic castration-resistant prostate cancer.

Alan H. Bryce, MD, discusses the accelerated approval of rucaparib (Rubraca) for the treatment of adult patients with BRCA mutation (germline and/or somatic)–associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor–directed therapy and a taxane-based chemotherapy.

Eric A. Klein, MD, discusses the importance of providing genomic testing to patients with prostate cancer.

Manoj K. Jain, MD, discusses diagnostic tracers in prostate cancer.

Manish Kohli, MD, discusses the use of enzalutamide (Xtandi) and apalutamide (Erleada) in patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Nicholas J. Vogelzang, MD, discusses the significance of the rucaparib approval for this patient population.

Phillip J. Koo, MD, discusses the need for next-generation imaging in prostate cancer.

Carlos E. Vargas, MD, discusses research with proton therapy in prostate cancer.

The FDA has approved rucaparib for the treatment of adult patients with BRCA-mutant recurrent, metastatic castration-resistant prostate cancer.

David F. Penson, MD, MPH, MMHC, discusses ongoing research in prostate cancer.

William L. Dahut, MD, discusses the future of genetic screening in prostate cancer.

Alanna K. Rahm, PhD, MS, discusses the challenges of implementing alternate delivery models for genetic counseling in prostate cancer.

Elisabeth I. Heath, MD, FACP, discusses developments in nonmetastatic castration-resistant prostate cancer (CRPC).

























































